Detailed Information on Publication Record
2022
Proton pump inhibitors use and risk of preeclampsia: A meta-analysis of pharmacoepidemiological studies
HUSSAIN, Mohammad Salman, Ambrish SINGH, Benny ANTONY, Jitka KLUGAROVÁ, M. Hassan MURAD et. al.Basic information
Original name
Proton pump inhibitors use and risk of preeclampsia: A meta-analysis of pharmacoepidemiological studies
Authors
HUSSAIN, Mohammad Salman, Ambrish SINGH, Benny ANTONY, Jitka KLUGAROVÁ, M. Hassan MURAD, Aarthi S. JAYRAJ, Alena LANGAUFOVÁ and Miloslav KLUGAR
Edition
38th International Conference on Pharmacoepidemiology: Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community, August 26–28, 2022, Copenhagen, Denmark, 2022
Other information
Language
English
Type of outcome
Konferenční abstrakt
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.600
Organization unit
Faculty of Medicine
ISSN
UT WoS
000859084401116
Tags
International impact
Změněno: 14/11/2022 08:46, Mgr. Tereza Miškechová
Abstract
V originále
Background: Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies described conflicting associations between the use of PPIs during pregnancy and preeclampsia risk. Objectives: To evaluate the association between PPIs use and risk of preeclampsia. Methods: Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and risk of bias assessment were performed independently by two investigators. Risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Results: This meta-analysis comprised of three studies involving 4 877 565 pregnant women, of whom 119 017 were PPIs users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was statistically significantly increased [ RR 1.27 (95% CI: 1.23 to 1.31)] although the increase was trivial in absolute terms (2 per 1000). Subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not statistically significantly increased [RR 1.04 (95% CI: 0.70–1.55)]. The certainty evaluated by GRADE in these estimates was low. Conclusions: PPIs use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.